€34.04
1.36% today
Xetra, Sep 16, 05:35 pm CET
ISIN
DE0005785604
Symbol
FRE
Sector

Fresenius Stock price

€34.04
+2.09 6.54% 1M
+8.88 35.29% 6M
+5.97 21.27% YTD
+3.92 13.01% 1Y
-6.79 16.62% 3Y
-11.38 25.06% 5Y
-4.48 11.62% 10Y
Xetra, Closing price Mon, Sep 16 2024
-0.47 1.36%
ISIN
DE0005785604
Symbol
FRE
Sector

Key metrics

Market capitalization €19.44b
Enterprise Value €32.43b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 10.32
EV/Sales (TTM) EV/Sales 1.45
P/S ratio (TTM) P/S ratio 0.87
P/B ratio (TTM) P/B ratio 1.02
Dividend yield 2.67%
Last dividend (FY22) €0.92
Revenue growth (TTM) Revenue growth -46.35%
Revenue (TTM) Revenue €22.36b
EBIT (operating result TTM) EBIT €1.35b
Free Cash Flow (TTM) Free Cash Flow €3.14b
Cash position €1.11b
EPS (TTM) EPS €-1.99
P/E forward 20.47
P/S forward 0.89
EV/Sales forward 1.49
Show more

Create a Free Account to create an Fresenius alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Fresenius Stock Analysis

Analyst Opinions

14 Analysts have issued a Fresenius forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Fresenius forecast:

Buy
79%
Hold
21%

Financial data from Fresenius

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
22,360 22,360
46% 46%
100%
- Direct Costs 17,162 17,162
45% 45%
77%
5,198 5,198
50% 50%
23%
- Selling and Administrative Expenses 1,635 1,635
54% 54%
7%
- Research and Development Expense 668 668
25% 25%
3%
2,895 2,895
51% 51%
13%
- Depreciation and Amortization 1,541 1,541
49% 49%
7%
EBIT (Operating Income) EBIT 1,354 1,354
53% 53%
6%
Net Profit -1,115 -1,115
211% 211%
-5%

In millions EUR.

Don't miss a Thing! We will send you all news about Fresenius directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fresenius Stock News

AD HOC NEWS
4 days ago
Die Aktien von Fresenius DE0005785604 setzen ihre schon länger andauernde Erholungsrally mit Schwung fort.
AD HOC NEWS
4 days ago
Die US-Bank JPMorgan hat Fresenius DE0005785604 von "Neutral" auf "Overweight" hochgestuft und das Kursziel von 37,60 auf 40,10 Euro angehoben.
marktEINBLICKE
3 months ago
Das Gesundheitsunternehmens Fresenius ist zuletzt mit seinem Konzernumbau und den Sparanstrengungen sehr gut vorangekommen.
More Fresenius News

Company Profile

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products, and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment comprises dialysis products and healthcare services. The Fresenius Kabi segment specializes intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios focuses on the private hospital operations. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The Corporate and Other segment includes the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.

Head office Germany
CEO Michael Sen
Employees 193,865
Founded 1912
Website www.fresenius.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today